Skip to content

Effect of Stellate Ganglion Block Combined with Intranasal Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Laparoscopic Resection for Gastrointestinal Malignancies

Effect of Stellate Ganglion Block Combined with Intranasal Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Laparoscopic Resection for Gastrointestinal Malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104345
Enrollment
Unknown
Registered
2025-06-16
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group D: Stellate Ganglion Block (SGB) with Intranasal Dexmedetomidine:Stellate ganglion block (SGB) combined with intranasal dexmedetomidine spray
Group D: Stellate Ganglion Block (SGB) with Intranasal Dexmedetomidine:Stellate ganglion block combined with intranasal spray of isovolumic saline

Sponsors

The First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=65 years, BMI 18.5–28 kg/m², and ASA physical status I–III; 2.Scheduled for elective laparoscopic resection of gastrointestinal malignancies under general anesthesia; 3.Surgical duration <=4 hours; 4.Voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Preoperative Pittsburgh Sleep Quality Index (PSQI) score >5; 2.Long-term or recent continuous use of opioids or psychoactive medications; 3.Diagnosis of obstructive sleep apnea-hypopnea syndrome (OSAHS); 4.Preoperative cognitive impairment or inability to communicate; 5.Severe trauma, infection, or other pathologies at the puncture site/surgical access route; 6.Upper respiratory tract infection within the past 2 weeks, or presence of respiratory cysts, tumors, or polyps. 7.Contraindications or allergies to related study medications; 8.Concurrent participation in other clinical trials.

Design outcomes

Primary

MeasureTime frame
the postoperative VAS score, HADS score, serological markers, and the incidence of adverse events within three days after surgery;Leeds Sleep Evaluation Questionnaire (LSEQ) score and Objectively measured sleep parameters;

Secondary

MeasureTime frame
Serological markers;Incidence of adverse events within the first 3 postoperative days;Postoperative VAS scores;Postoperative Hospital Anxiety and Depression Scale score;

Countries

China

Contacts

Public ContactZhong Maolin

The First Affiliated Hospital of Gannan Medical University

zml8802@163.com+86 797 8689060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026